New Techniques for
Cellulite Treatment
TriActive for
Cellulite
By
MSP Staff | Published
09/10/2006
Cellulite is a four-letter word for many
women, and some of them will do just about
anything to make it go away. Women take
measures like scrubbing, massage or more
drastic measures to eliminate the cellulite.
There is now something new.
The Food and Drug Administration recently
approved a laser to treat the unwanted
dimpling. It has been an ongoing fight for
many people, especially women, since anyone
can remember.
"I sit down all day," Gretchen Defazio said.
"I work at a desk seven hours a day."Defazio,
46, and her daughter, Nicole, 20, do a lot
of things together, and that includes
tackling cellulite. She said she did
everything right but she just could not get
rid of the extra cellulite. When they heard
about something new, an FDA-approved laser
that reduced the dimpling, they did not
hesitate.
"We're trying to reduce the appearance of
cellulite on the back of Gretchen's legs," a
technician said. "The smoothing and the
toning will help eliminate the dimpling
look.
It is all done with a laser known as
TriActive. As its name
suggests, the laser works three ways. "The
cooling system, the laser system and
massaging," laser removal specialist Dr.
Michael Coppa said.
The Defazios said it is soothing."It's like
little fingers massaging you," Gretchen
Defazio said. Coppa said the massaging helps
with the lymphatic draining.
"You're actually pushing [the cellulite]
away," he said. "The cooling helps with the
fluid retention, and the laser helps with
stimulation of blood vessels, collagen and
the fibers under the skin, which helps with
the tightening of the skin.
"It takes a total of about 16 sessions done
twice weekly to achieve the best results.
Restylane for Cellulite?
By
MSP Staff - Published
09/10/2006
Cellulite- it's that dimpled, lumpy, bumpy
skin. No one wants it, but Patricia Izzo
says she has found a way to get rid of it.
Her solution is an injectable filler called
Restylane. It is approved by the FDA for
facial wrinkles, but dermatologist Jeanette
Graf says it is working wonders on legs.
"It can be injected very superficially, as
well as deep, so you can get it at all
levels of skin," Dr. Graf said. Restylane is
made of hyaluronic acid, which occurs
naturally in the body. It fills in the
dimples to create a smooth appearance.
"I saw the effects almost immediately," said
Izzo, a patient. Results should last between
four and six months. That convinced Eileen
Flannery to try it.
"I like the idea that it's a one-time thing,
basically," she said. "I'm not putting
something on every night. I'm not coming
back repeatedly." Flannery's dimples
disappeared, but she did have a little
bruising -- a common side effect that goes
away within days.
But one expert warns that the treatment
might not be for everyone. "Ideally, this is
best suited for someone with very specific,
deep dimples, and a limited number of them,"
said dermatologist Ranella Hirsch.
Dr. Hirsch, who is with the society of
cosmetic dermatology and aesthetic surgery,
says the more cellulite you have, the more
injections you'll need. That can add up to
hundreds or thousands of dollars.
Syneron
VelaSmooth New Countour Applicator for
Cellulite Reduction
By
MSP Staff - Published
09/10/2006
Syneron Medical Ltd., an innovator in the
development, marketing and sales of elosTM
combined-energy medical aesthetic devices,
today introduces the new Contour ApplicatorTM,
a smaller applicator for use with its
VelaSmoothTM System. The Contour
Applicator, which is ergonomically designed
to fit comfortably in the user's hand, is
designed to facilitate spot treatments in
hard-to-reach areas, enhancing use of the
device for cellulite reduction.
Since U.S. FDA clearance in June 2005, more
than 100,000 patients have been treated with
the VelaSmooth. After quickly becoming the
preferred cellulite treatment of physicians,
the VelaSmooth, designed with
elos-technology, now has the largest
worldwide installed base of any energy-based
device for cellulite reduction.
The VelaSmooth is currently under study to
evaluate use of the device to reduce thigh
circumference. In an initial publication in
"The Journal of Cosmetic and Laser Therapy,"
Alster et al. have reported promising early
results in circumference reduction of thighs
treated by the VelaSmooth.
Dr. Tina Alster, principal investigator in
the study and director of the Washington
Institute of Dermatologic Laser Surgery and
clinical professor of dermatology at
Georgetown University, commented that, "In
our published clinical study, we found the
VelaSmooth to be effective in significantly
reducing thigh circumference as well as
improving the clinical appearance of
cellulite."
VelaSmooth is a non-invasive device based on
Syneron's proprietary elos technology -- a
combination of bi-polar RF and light energy
-- and is specifically designed to improve
skin texture, reduce the appearance of
cellulite and reduce localized fat deposits.
The VelaSmooth system involves the
simultaneous application of light energy to
the tissue at a controlled infrared
wavelength, conducted RF energy and
mechanical manipulations of the skin and fat
layer.
"The Contour Applicator has been well
received by patients," said Dr. Gerald Boey,
G.P. "I'm very pleased with the results and
expect new patients introduced to the system
will also be very satisfied."
Cellulite treatments have increased 81
percent since 2000, according to the
American Society of Plastic Surgeons. Due to
soaring consumer demand for cellulite
treatment and its commitment to continually
improving product line safety and efficacy,
Syneron created the VelaSmooth Contour
Applicator to further enhance patient
results and treatment efficiency. This new
device allows for fewer patient treatments
and reduces strain on technicians who
conduct the procedure.
In clinical trials, patients have been able
to reduce their visits by up to 50 percent
from the original treatment protocol. For
practitioners, the smaller Contour
Applicator is easier to use and requires
less physical effort to operate.
Studies of VelaSmooth treatments found that
approximately 90 percent of patients
experienced an overall clinical improvement
on the area treated, with about 94 percent
of patients pursuing treatment of other body
areas.
